Daratumumab approved for first line treatment in Israel
Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel. “Health Basket” Each year, the Israel Ministry of Health nominates a Health Committee to discuss and recommend approval and extension for a new “health basket,” which includes all the services, medications, supplies, and…